The technical setup shows trend continuation, not reversal. RSI at 38.69 is making lower highs and lower lows alongside price, with no confirmed bullish divergence. MACD is negative at −1.27 and widening, having stayed below zero for a month. CL broke below the 200 SMA around September 8 and has spent roughly 13 trading sessions confirming the breakdown.

• RSI at 38.69
• MACD at −1.27, signal at −1.14, histogram at −0.13
• 200 SMA breakdown around September 8
• 13 trading sessions below 200 SMA
• No confirmed bullish divergence on RSI

↩ rebuts: “Bull's claim that RSI 38.69 represents exhaustion and a buying opportunity”

Operating margin is compressing despite gross margin expansion, revealing defensive spending posture rather than true margin leverage. Gross margin expanded ~100bps while operating margin contracted 260bps from 2024 to Q2 2026, with all gross margin gains consumed by SG&A reinvestment.

• Gross Margin: 2024: 60.5%, Q2 2026: 61.5%
• Operating Margin: 2024: 21.5%, Q2 2026: 18.9%
• Operating margin contracted 260bps over same period
• SG&A reinvestment in North America premium toothpaste advertising

↩ rebuts: “Bull's celebration of 61.5% gross margin as proof of pricing power and execution”

The $919M Hill's impairment represents structural deterioration in the $4B pet nutrition business, not a one-time charge. A ~23% goodwill write-down means management believes future cash flows are roughly 23% lower than previously projected, with disruption from fresh and direct-to-consumer pet food brands.

• $919M Hill's impairment
• Hill's revenue roughly $4B
• ~23% goodwill write-down on Hill's
• Disruption from Farmer's Dog, Chewy, JustFoodForDogs

↩ rebuts: “Bull's characterization of impairment as a one-time, non-recurring event”

CL's balance sheet shows severe equity hollowing from buybacks with dangerous working capital position. Total stockholders' equity is $236M against $28.9B in treasury stock, and current liabilities exceeded current assets by $1.14B at YE 2025.

• Total stockholders' equity: $236 million
• Treasury stock: $28.9 billion
• P/B ratio of 290x
• Current ratio of 1.03 in Q2 2026
• Current ratio of 0.83 at year-end 2025
• Negative working capital of $1.14B at YE 2025
• FCF of $3.6B

↩ rebuts: “Bull's dismissal of P/B ratio as mechanical inflation”

Haleon (Sensodyne) is gaining shelf space at Walmart and Target—the two largest U.S. retailers accounting for roughly 50%+ of U.S. consumer health sales—and winning in sensitivity toothpaste, the highest-growth segment. Private label has grown to 15-20%+ category share, breaking CL's pricing power thesis.

• CL 40%+ global toothpaste market share in flat-to-declining category
• Haleon gaining shelf space at Walmart and Target
• Walmart and Target account for 50%+ of U.S. consumer health sales
• Private label 15-20%+ category share in many markets
• Private label captures 30%+ margin share away from branded manufacturers

↩ rebuts: “Bull's claim that 40%+ market share is an unassailable moat”

The dividend yield of 2.46% versus 5% 10-year Treasury creates a 254bps spread disadvantage, explaining CL's 16.5% six-month underperformance versus S&P 500 as income allocators rotate to risk-free Treasuries. Real dividend growth after inflation is approximately 0-2%.

• Dividend yield: 2.46%
• 10-year Treasury yield: 5%
• Yield spread: 254 basis points
• CL underperformed S&P 500 by 16.5% over six months
• Dividend growth roughly 3-5% annually
• Real dividend growth after inflation: approximately 0-2%

↩ rebuts: “Bull's dividend track record thesis as a reason to buy”

CL's 21x forward P/E is at its 10-year average despite material deterioration in fundamentals and technical breakdown, warranting multiple compression to 18-19x and fair value of $74-78.

• Forward P/E of 21x
• CL's 10-year average forward P/E: 20-22x
• Appropriate multiple in deteriorating environment: 18-19x
• Fair value estimate: $74-78

↩ rebuts: “Bull's claim that 21x is a reasonable entry point for a quality compounder”

Forward EPS of $4.10 is a consensus estimate vulnerable to downward revision. Any Q3 2026 earnings miss (realistic risks: Haleon shelf-space volume loss, EMFX weakness, Hill's pressure, input cost inflation) could trigger a 15-20% drawdown to $70-72.

• Forward EPS of $4.10
• 5% earnings miss = $0.98 EPS, forward EPS drops to $4.00
• Recipe for 15-20% drawdown from $86 to $70-72
• Live risks: Haleon volume loss, EMFX weakness, Hill's pressure, energy/input cost squeeze

↩ rebuts: “Bull's claim that 60%+ earnings rebound is mechanical”

Rising yields create duration pressure on CL's bond-proxy valuation. As 10-year yields rise, the discount rate applied to CL's dividend stream rises, compressing the present value of all future dividends. Trump-Xi tariff risk creates asymmetric input cost pressure for a company with 40% EM revenue exposure.

• 10-year yields at 5%
• CL 0.32 beta
• CL 40% EM revenue exposure
• Tariff risk: higher COGS on chemicals, packaging, palm oil derivatives from Asia
• Weaker EM demand from retaliatory tariffs

↩ rebuts: “Bull's claim that late-cycle defensive rotation favors CL and hawkish Fed is neutral”

The bull's asymmetric risk/reward math of 2.6-to-1 is flawed. Realistic downside target is $82-83 consolidation zone ($3+ risk), while realistic upside to reclaim 200 SMA is only $1.54, making the trade roughly 1-to-1 symmetric—favoring the seller in a downtrend.

• Stop below $84.70: risk = $1.36
• Realistic downside to $82-83: $3+ risk
• Upside to 200 SMA at $87.60: only $1.54
• Bull's asymmetric ratio of 2.6-to-1 is overstated

↩ rebuts: “Bull's claimed 2.6-to-1 reward-to-risk ratio from $84.47 stop to $90.23 target”